Apheresis market to hit $4.4b by 2031 on autoimmune, surgical demand

Asia Pacific is estimated to record the highest CAGR.

The apheresis market is projected to grow from about $3.02b in 2026 to $4.41b by 2031, at a compound annual growth rate (CAGR) of 7.9%, according to a MarketsandMarkets report.

The report attributes the growth to the rising prevalence of autoimmune and neurological diseases, along with an increase in surgical procedures and trauma cases.

In addition, the expansion of healthcare in developing regions and wider access to hospitals and therapies have created new markets for apheresis.

Based on type, the market can be classified into two segments—donor apheresis and therapeutic apheresis—with the former anticipated to register a high CAGR throughout the forecast period.

By procedure, plasmapheresis is expected to grow at the highest CAGR, driven by high demand for plasma-based therapies and an increase in the use of source plasma to manufacture immunoglobulin, albumin, and coagulation factors.

Whilst North America is expected to hold the largest share of the market, the Asia Pacific is estimated to record the highest CAGR during the forecast period.

Factors contributing to the growth in the region include healthcare infrastructure expansion, increased awareness of blood donation and plasma collection, and increased investments in healthcare transformation in emerging economies such as China and India.